Lifestyle Walking Intervention for Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial

BACKGROUND

Physical activity is pivotal in managing heart failure with reduced ejection fraction, and walking integrated into daily life is an especially suitable form of physical activity. This study aimed to determine whether a 6-month lifestyle walking intervention combining self-monitoring and regular telephone counseling improves functional capacity assessed by the 6-minute walk test (6MWT) in patients with stable heart failure with reduced ejection fraction compared with usual care.

METHODS

The WATCHFUL trial (Pedometer-Based Walking Intervention in Patients With Chronic Heart Failure With Reduced Ejection Fraction) was a 6-month multicenter, parallel-group randomized controlled trial recruiting patients with heart failure with reduced ejection fraction from 6 cardiovascular centers in the Czech Republic. Eligible participants were ≥18 years of age, had left ventricular ejection fraction <40%, and had New York Heart Association class II or III symptoms on guidelines-recommended medication. Individuals exceeding 450 meters on the baseline 6MWT were excluded. Patients in the intervention group were equipped with a Garmin vívofit activity tracker and received monthly telephone counseling from research nurses who encouraged them to use behavior change techniques such as self-monitoring, goal-setting, and action planning to increase their daily step count. The patients in the control group continued usual care. The primary outcome was the between-group difference in the distance walked during the 6MWT at 6 months. Secondary outcomes included daily step count and minutes of moderate to vigorous physical activity as measured by the hip-worn Actigraph wGT3X-BT accelerometer, NT-proBNP (N-terminal pro-B-type natriuretic peptide) and high-sensitivity C-reactive protein biomarkers, ejection fraction, anthropometric measures, depression score, self-efficacy, quality of life, and survival risk score. The primary analysis was conducted by intention to treat.

RESULTS

Of 218 screened patients, 202 were randomized (mean age, 65 years; 22.8% female; 90.6% New York Heart Association class II; median left ventricular ejection fraction, 32.5%; median 6MWT, 385 meters; average 5071 steps/day; average 10.9 minutes of moderate to vigorous physical activity per day). At 6 months, no between-group differences were detected in the 6MWT (mean 7.4 meters [95% CI, -8.0 to 22.7]; P=0.345, n=186). The intervention group increased their average daily step count by 1420 (95% CI, 749 to 2091) and daily minutes of moderate to vigorous physical activity by 8.2 (95% CI, 3.0 to 13.3) over the control group. No between-group differences were detected for any other secondary outcomes.

CONCLUSIONS

Whereas the lifestyle intervention in patients with heart failure with reduced ejection fraction improved daily steps by about 25%, it failed to demonstrate a corresponding improvement in functional capacity. Further research is needed to understand the lack of association between increased physical activity and functional outcomes.

REGISTRATION

URL: https://www.clinicaltrials.gov; Unique identifier: NCT03041610.

Computed tomography is better than echocardiography in predicting balloon-expandable transcutaneous implantation valve size in a real-world clinical practice single-center study

AIMS

Transcatheter aortic valve replacement (TAVR) has become the standard of care for selected patients with severe aortic stenosis. Multidetector computed tomography (MDCT) and transoesophageal 2D/3D (two-dimensional/three-dimensional) echocardiography (ECHO) are used for aortic annulus (AA) sizing. The aim of this study was to compare the accuracy of AA sizing by ECHO versus MDCT for Edwards Sapien balloon expandable valve in a single center.

METHODS AND RESULTS

Data from 145 consecutive patients with TAVR (Sapien XT or Sapien S3) were analyzed retrospectively. A total of 139 (96%) patients had favorable outcomes after TAVR (at most mild aortic regurgitation and only one valve implanted). The 3D ECHO AA area and area-derived diameter were smaller than the corresponding MDCT parameters (464 ± 99 vs. 479 ± 88 mm2 , p < .001, and 24.2 ± 2.7 vs. 25.0 ± 5.5 mm, p = .002, respectively). The 2D ECHO annulus measurement was smaller than both the MDCT and 3D ECHO area-derived diameters (22.6 ± 2.9 vs. 25.0 ± 5.5 mm, p = .013, and 22.6 ± 2.9 vs. 24.2 ± 2.7 mm, p < .001, respectively) but larger than the minor axis diameter of the AA derived from MDCT and 3D ECHO by multiplanar reconstruction (p < .001). The 3D ECHO circumference-derived diameter was also smaller than the MDCT circumference-derived diameter (24.3 ± 2.5 vs. 25.0 ± 2.3, p = .007). The sphericity index by 3D ECHO was smaller than that by MDCT (1.2 ± .1 vs. 1.3 ± .1, p < .001). In up to 1/3 of the patients, 3D ECHO measurements would have predicted different (generally smaller) valve size than was the valve size implanted with favorable result. The concordance of the implanted valve size with the recommended size based on preprocedural MDCT and 3D ECHO AA area was 79.4% versus 61% (p = .001), and for the area-derived diameter, the concordance was 80.1% versus 61.7% (p = .001). 2D ECHO diameter concordance was similar to MDCT (78.7%).

CONCLUSIONS

3D ECHO AA measurements are smaller than MDCT measurements. If 3D ECHO-based parameters alone are used to size the Edwards Sapien balloon expandable valve, then the selected valve size would have been smaller than the valve size implanted with favorable result in 1/3 of the patients. MDCT preprocedural TAVR assessment should be the preferred method over 3D ECHO in routine clinical practice to determine Edwards Sapien valve size.

Capture threshold of bipolar and unipolar pacing of left ventricle via coronary sinus branch: longitudinal study

Introduction

The aim of this paper is to first monitor the changes in the capture threshold of endovascularly placed leads for left ventricle pacing, second to compare the pacing configurations, and third to verify the effect of Steroid elution for endovascular leads.

Sample and Method

The study included 202 consecutive single centre patients implanted with the Quartet™ lead (St. Jude Medical). The capture threshold and related lead parameters were tested during implantation, on the day of the patient's discharge, and 3, 9, and 15 months after implantation. The electrical energy corresponding to the threshold values for inducing ventricular contraction was recorded for subgroups of patients with bipolar and pseudo-unipolar pacing vectors and electrodes equipped with and without a slow-eluting steroids. The best setting for the resynchronization effect was generally chosen. Capture threshold was taken as a selection criterion only if there were multiple options with (expected) similar resynchronization effect.

Results and Discussion

The measurements showed that the ratio of threshold energies of UNI vs. BI was 5× higher (p < 0.001) at implantation. At the end of the follow-up, it dropped to 2.6 (p = 0.012). The steroid effect in BI vectors was caused by a double capture threshold in the NSE group compared to the SE group (p < 0.001), increased by approximately 2.5 times (p < 0.001). The study concludes that after a larger initial increase in the capture threshold, the leads showed a gradual increase in the entire set. As a result, the bipolar threshold energies increase, and the pseudo-unipolar energies decrease. Since bipolar vectors require a significantly lower pacing energy, battery life of the implanted device would improve. When evaluating the steroid elution of bipolar vectors, we observe a significant positive effect of a gradual increase of the threshold energy.

Midterm outcomes of mini-invasive surgical and hybrid ablation of atrial fibrillation

BACKGROUND

We evaluated the feasibility and effectiveness of thoracoscopic and a staged surgical and transcatheter ablation technique to treat stand-alone atrial fibrillation (AF).

METHODS

. Between 2009 and 2016, a cohort of 65 patients underwent bilateral totally thoracoscopic ablation of symptomatic paroxysmal AF (n=30; 46%), persistent AF (n=18; 28%) or long-standing persistent AF (n=17; 26%) followed by catheter ablation in case of AF recurrence. Surgical box lesion procedure included bilateral pulmonary vein and left atrial posterior wall ablation using irrigated bipolar radiofrequency with documentation of conduction block.

RESULTS

There were no intra- or peri-operative ablation-related complications. There was no operative mortality, no myocardial infarction, and no stroke. Skin-to-skin procedure time was 120.5 ± 22.0 min and the postoperative average length of stay was 8.1 ± 3.0 days. At discharge, 60 patients (92%) were in sinus rhythm. Median follow-up time was 866 days (IQR, 612-1185 days). One-year success rate after surgical procedure was 78% (off antiarrhythmic drugs). Eleven patients (17%) underwent catheter re-ablation. Sixty (92%) patients were free of atrial fibrillation after hybrid ablation (on demand) at 1 year follow up after the last ablation. The success at 24-months was achieved in 96% (paroxysmal) and 78% (persistent) patients. At the last follow-up control, 69% patients discontinued oral anticoagulant therapy.

CONCLUSIONS

. Combination of mini-invasive surgical and endocardial treatment (two-stage hybrid procedure) is a safe and effective method for the treatment of isolated (lone) AF. This procedure provided good midterm outcomes.

Cardiac resynchronization therapy in clinical responders: right ventricular echocardiographic changes at mid-term follow-up

OBJECTIVE

The objective of this study was to assess the mid-term effects of cardiac resynchronization therapy on systolic function and remodelling of the right ventricle in clinical responders and non-responders.

METHODS

A biventricular system was implanted between July 2005 and May 2008 in 58 patients with heart failure NYHA class II-IV. At baseline, three and 15 months after implantation, the following parameters were determined: NYHA class, quality of life, six-minute walk test, echocardiography including assessment of right ventricular systolic function by tricuspid annular plane systolic excursion and by pulsed tissue Doppler imaging (myocardial peak systolic velocity was measured at the tricuspid annulus). We also assessed the presence of ventricular dyssynchrony.

RESULTS

There were no significant changes after three months of cardiac resynchronization therapy on right ventricular systolic function and remodelling in responders and non-responders. Among responders, we found a statistically significant improvement of right ventricular systolic function and also a significant decrease in the size of the right ventricle after 15 months of therapy (systolic excursion before therapy 17.8 +/- 4.0 mm vs. 19.4 +/- 3.7 mm, P < 0.05, after therapy; peak systolic velocity initially 11.9 +/- 2.9 cm/s vs 12.7 +/- 3.2 cm/s; right ventricle size before therapy 29.3 +/- 5.0 mm vs. 27.8 +/- 4.2 mm, P < 0.05, after therapy. These changes were not observed in non-responders.

CONCLUSIONS

Fifteen months after cardiac resynchronization therapy, we found a statistically significant improvement of right ventricular systolic function and a significant reduction of right ventricular size in responders to cardiac resynchronization therapy.

Echocardiographic changes after cardiac resynchronisation therapy

BACKGROUND AND AIM

The aim of this prospective study was to evaluate echocardiographic changes in clinical responders and nonresponders after 3 and 15 months of cardiac resynchronisation therapy (CRT).

METHODS

Fifty eight patients in whom a biventricular system was implanted between 2005 and 2008 were followed up at 3 and at 15 months. Clinical and echocardiography parameters including intra- and interventricular dyssynchrony were assessed at baseline and after 3 and 15 months of CRT. Every patient in whom quality of life, New York Heart Association (NYHA) class and/or 6-minute walk test (6MWT) improved (improvement of ≥ 1 NYHA class, 6MWT by more than 10%), and who was neither in hospital for heart failure nor died for cardiac reasons, was categorised as a clinical responder.

RESULTS

In the responders' group, we found a significant improvement of right ventricular systolic function and a decrease in the size of the right ventricle (RV) only after 15 months (tricuspid annular plane systolic excursion [TAPSE] 17.8 ± 4.0 mm to 19.4 ± 3.7 mm, p 〈 0.05, RV diameter 29.3 ± 5.0 mm to 27.8 ± 4.2 mm, p 〈 0.05). Significant improvement of other monitored parameters occurred 3 months after CRT implantation: left ventricle (LV) end-diastolic diameter 70.5 ± 7.8 mm to 66.1 ± 8.3 mm, p 〈 0.001, LV ejection fraction 22.0 ± 5.4% to 27.1 ± 9.8%, p 〈 0.05, pulmonary artery pressure (peak gradient of tricuspid regurgitation) 37.1 ± 14.8 mm Hg to 27.6 ± 8.9 mm Hg, p 〈 0.001, tricuspid regurgitation (grade) 1.9 ± 0.9 to 1.5 ± 0.6, p 〈 0.05, mitral regurgitation (grade) 2.6 ± 0.9 to 2.2 ± 0.9, p 〈 0.001, LV dP/dt max (peak positive rate of pressure rise [slope of mitral regurgitant jet]) 482.4 ± 155.4 mm Hg/s to 981.2 ± 654.5 mm Hg/s, p 〈 0.001, velocity time integral (VTI) in LV outflow tract (LVOT) 14.1 ± 4.3 cm to 16.7 ± 4.1 cm, p 〈 0.001. In the group of nonresponders, only 2 parameters improved significantly: LV dP/dt max 561.2 ± 347.9 mm Hg/s to 1024.5 ± 745.3 mm Hg/s, p 〈 0.001, and LVOT VTI 14.5 ± 3.0 cm to 16.3 ± 2.9 cm, p 〈 0.001. Other echocardiographic parameters did not show any important changes, and no changes occurred between 3 and 15 months. On the contrary, after 15 months we saw significant progression of tricuspid regurgitation in nonresponders. In multivariate analysis, combination of baseline delay between time to peak systolic velocity in ejection phase at basal septal and basal lateral segments (Ts-lateral-septal delay) and serum creatinine was a strong predictor of clinical CRT response (area under curve was 0.80, percentage of correct decision was 82%).

CONCLUSIONS

In the group of responders, significant changes of most monitored echocardiographic parameters were observed 3 months after CRT implantation. The only parameters which changed significantly after 15 months, but not previously, were the systolic function of the RV and the decrease in the RV size. In the group of nonresponders, these changes were not observed.

Thoracoscopic left ventricular lead implantation

OBJECTIVE

Cardiac resynchronization therapy is a therapeutic option in patients with chronic heart failure. Epicardial lead implantation for biventricular pacing is usually the method of second choice after failed coronary sinus cannulation. The present study describes an initial experience with minimally invasive surgical lead implantation using thoracoscopy.

METHODS

Since August 2008, a total of 17 patients (mean age 69.6 + 11.1 years) with congestive heart failure, NYHA functional class 3.1 +/- 0.4, and depressed ejection function (24.8% +/- 5.7%) were referred for surgery because of failed left ventricular lead implantation through the coronary sinus. Under single-lung ventilation and video-assisted thoracoscopy, epimyocardial steroid-eluting screw-in leads were implanted on the left ventricular free wall.

RESULTS

There were no in-hospital deaths or major co-morbidities. The mean skin-to-skin operating time was 115.9 +/- 32.1 min, and the post-operative average length of stay was 8.4 +/- 2.5 days. Intraoperative acute threshold capture of the left ventricular lead was 0.88 +/- 0.54 V/0.5 ms, and the value of lead impedance was 434.7 +/- 110.8 Omega. Extension to a small thoracotomy was necessary in 1 patient to stop epicardial vein bleeding.

CONCLUSION

Minimally invasive left ventricular lead implantation is a safe procedure with excellent acute threshold capture.

Hemostatic changes before and during electrophysiologic study and radiofrequency catheter ablation

We sought to investigate specific hemostasis activation markers during electrophysiologic study (EPS) with consequent radiofrequency catheter ablation (RFA). Sixty patients were studied prospectively during routine EPS with RFA for paroxysmal supraventricular tachycardia. Blood samples were drawn before the insertion of venous sheaths (T0), at the end of EPS (T1), and 30 min after completion of RFA (T2). To study coagulation and fibrinolytic and platelet activity, we measured concentrations of thrombin-antithrombin III (TAT), D-dimers (DD), plasminogen activator inhibitor type 1 (PAI-1), tissue-type plasminogen activator (t-PA), and circulating platelet aggregates. The results are expressed as median and show 95% confidence levels. Levels of DD increased from 0.24 mg/L at T0 to 0.37 mg/L at T1 (P < 0.001) and to 0.59 mg/L at T2 (P < 0.001). TAT levels increased from 5.29 μg/L at T0 to 35.80 μg/L at T1 (P < 0.001) and decreased to 26.30 μg/L at T2 (P < 0.001). PAI-1 concentration decreased from 30.10 μg/L at T0 to 26.4 μg/L at T1 (P < 0.001). t-PA at T2 increased to 5.10 μg/L from 4.75 μg/L at T1 (P = 0.001). No other differences between corresponding medians were statistically significant (P > 0.05). We found that concentrations of DD at T2 versus T1 depended on the number of radiofrequency energy applications (r (S) = 0.387; P = 0.002). Marked platelet activation was observed from the start of the procedure, without changes during the procedure.

High-sensitivity troponin T as a marker of myocardial injury after radiofrequency catheter ablation

Background

The aim of our study was to monitor radiofrequency catheter ablation-induced myocardial damage by measuring high-sensitivity cardiac troponin T (hs-cTnT).

Methods

Serum concentrations of hs-cTnT (Elecsys 2010 system, Roche) were measured in 73 healthy blood donors and serially in 27 patients who had samples taken both before and 24 h after radiofrequency ablation (RFA) for atrioventricular nodal re-entry tachycardia (AVNRT), atrial fibrillation (AF) or right atrial flutter (AFL).

Results

Significant increases of hs-cTnT were seen in patients after RFA (AVNRT: P = 0.0115, AF: P = 0.0011, AFL: P = 0.0009). Postprocedural serum hs-cTnT correlated with the number of radiofrequency applications and with the duration of RFA procedure. Spearman's coefficient of rank correlation ( r) were as follows: hs-cTnT versus RFA duration: r = 0.771 ( P < 0.001); hs-cTnT versus number of pulses: r = 0.708 ( P < 0.001). Patients with the diagnosis of AVNRT had lower serum hs-cTnT concentration after RFA compared with AFL ( P < 0.0001) and AF ( P < 0.0001) patients.

Conclusions

Our data indicate that RFA causes a significant increase of serum hs-cTnT concentration that could be used to monitor myocardial injury.

Longterm remission of left posterior fascicular ventricular tachycardia due to mechanical trauma

We present a case of a 28 year old woman with paroxysmal left posterior fascicular ventricular tachycardia (LPFVT). Ventricular tachycardia was not inducible after completing of left ventricle 3D reconstruction. Even though catheter ablation was not performed, no LPFVT recurrence has been documented during 60 months follow-up. We surmise that we caused mechanical trauma during the mapping of the posterior fascicle that damaged arrhythmogenic structures and subsequently led to long term remission of the left posterior fascicular ventricular tachycardia.

Bland-White-Garland syndrome in adults: sudden cardiac death as a first symptom and long-term follow-up after successful resuscitation and surgery

Two cases (a 23-year-old man and a 33 year-old-woman) with Bland-White-Garland (BWG) syndrome (an anomalous origin of the left coronary artery from the pulmonary artery) are presented. Their first symptom was survived sudden cardiac death. Both patients underwent surgical repair. One patient received an implantable defibrillator because of serious structural changes in the left ventricle and symptomatic non-sustained ventricular tachycardia; the second patient is free of therapy. During long-term follow-up (10.5 and 4.5 years, respectively), ventricular tachyarrhythmias did not recur. Both cases show good long-term prognosis in resuscitated adult patients after surgical repair for BWG syndrome regardless of the presence of structural changes.

Cavotricuspid Isthmus Catheter Ablation Across an Inferior Vena Cava Filter

Patients who suffer from recurrent thromboembolic events often receive an inferior vena cava (IVC) filter. There are few data available regarding treatment of this patient population with catheterization interventions, especially catheter ablation. We report a case of cavotricuspid isthmus catheter ablation across an IVC filter.

Characteristics and short-term survival of individuals with out-of-hospital cardiac arrests in the East Bohemian region

AIM

We describe survival after admission to hospital from out-of-hospital cardiac arrest (OHCA) in the East Bohemian region, according to the Utstein Style guidelines and have identified the main diagnosis including in those who died and had an autopsy.

PATIENT GROUP

Over a period of 29 months we used a questionnaire supplied to 24 rescue stations, to identify 718 individuals (511 men and 207 women, aged 16-97 years) with confirmed cardiac arrest who were considered for resuscitation.

RESULTS

Out of 560 patients in whom cardiopulmonary resuscitation for OHCA of confirmed cardiac aetiology was attempted, 350 patients (62.5%) died in the field and 61 (10.9%) died during transport. Hospital admission was achieved in 149 cases (26.6%) and, of these, 96 patients died. Fifty-three patients (9.5%) were discharged home alive, 36 (6.4%) with an intact CNS. The first monitored rhythm showed asystole in 264 cases (47.1%) followed by ventricular fibrillation in 227 cases (40.5%). The main diagnosis of coronary heart disease (CHD) was established clinically in 467 cases (83.4%). In 175 autopsy reports this diagnosis was noted in 152 cases (86.9%).

CONCLUSION

Of patients resuscitated for OHCA of cardiac aetiology, 9.5% survived to leave the acute hospital. CHD was the principle diagnosis in the entire group and this correlated with the same finding in the group of patients who received an autopsy.

Similar turnover and shedding of the cellular prion protein in primary lymphoid and neuronal cells

The cellular prion protein (PrP(C)) is essential for pathogenesis and transmission of prion diseases. Although prion replication in the brain is accompanied by neurodegeneration, prions multiply efficiently in the lymphoreticular system without any detectable pathology. We have used pulse-chase metabolic radiolabeling experiments to investigate the turnover and processing of PrP(C) in primary cell cultures derived from lymphoid and nervous tissues. Similar kinetics of PrP(C) degradation were observed in these tissues. This indicates that the differences between these two organs with respect to their capacity to replicate prions is not due to differences in the turnover of PrP(C). Substantial amounts of a soluble form of PrP that lacks the glycolipid anchor appeared in the medium of splenocytes and cerebellar granule cells. Soluble PrP was detected in murine and human serum, suggesting that it might be of physiological relevance.

Binding of disease-associated prion protein to plasminogen

Transmissible spongiform encephalopathies are associated with accumulation of PrP(Sc), a conformer of a cellular protein called PrP(C). PrP(Sc) is thought to replicate by imparting its conformation onto PrP(C) (ref. 1), yet conformational discrimination between PrP(C) and PrP(Sc) has remained elusive. Because deposition of PrP(Sc) alone is not enough to cause neuropathology, PrP(Sc) probably damages the brain by interacting with other cellular constituents. Here we find activities in human and mouse blood which bind PrP(Sc) and prion infectivity, but not PrP(C). We identify plasminogen, a pro-protease implicated in neuronal excitotoxicity, as a PrP(Sc)-binding protein. Binding is abolished if the conformation of PrP(Sc) is disrupted by 6M urea or guanidine. The isolated lysine binding site 1 of plasminogen (kringles I-III) retains this binding activity, and binding can be competed for with lysine. Therefore, plasminogen represents the first endogenous factor discriminating between normal and pathological prion protein. This unexpected property may be exploited for diagnostic purposes.

Neuroinvasion of prions: insights from mouse models

The prion was defined by Stanley B. Prusiner as the infectious agent that causes transmissible spongiform encephalopathies. A pathological protein accumulating in the brain of scrapie-infected hamsters was isolated in 1982 and termed prion protein (PrPSc). Its cognate gene Prnp was identified more than a decade ago by Charles Weissmann, and shown to encode the host protein PrP(C). Since the latter discovery, transgenic mice have contributed many important insights into the field of prion biology, including the understanding of the molecular basis of the species barrier for prions. By disrupting the Prnp gene, it was shown that an organism that lacks PrP(C) is resistant to infection by prions. Introduction of mutant PrP genes into PrP-deficient mice was used to investigate the structure-activity relationship of the PrP gene with regard to scrapie susceptibility. Ectopic expression of PrP in PrP knockout mice proved a useful tool for the identification of host cells competent for prion replication. Finally, the availability of PrP knockout mice and transgenic mice overexpressing PrP allows selective reconstitution experiments aimed at expressing PrP in neurografts or in specific populations of haemato- and lymphopoietic cells. The latter studies have allowed us to clarify some of the mechanisms of prion spread and disease pathogenesis.